Cargando…
HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Masson SAS.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445795/ https://www.ncbi.nlm.nih.gov/pubmed/34563798 http://dx.doi.org/10.1016/j.retram.2021.103312 |
| _version_ | 1784568728417992704 |
|---|---|
| author | Bouayad, Abdellatif |
| author_facet | Bouayad, Abdellatif |
| author_sort | Bouayad, Abdellatif |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8445795 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Masson SAS. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84457952021-09-17 HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination Bouayad, Abdellatif Curr Res Transl Med Letter to the Editor Elsevier Masson SAS. 2021-10 2021-09-17 /pmc/articles/PMC8445795/ /pubmed/34563798 http://dx.doi.org/10.1016/j.retram.2021.103312 Text en © 2021 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Bouayad, Abdellatif HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination |
| title | HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination |
| title_full | HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination |
| title_fullStr | HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination |
| title_full_unstemmed | HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination |
| title_short | HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination |
| title_sort | hla and pf4 antibody production after adenoviral vector sars-cov-2 vaccination |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445795/ https://www.ncbi.nlm.nih.gov/pubmed/34563798 http://dx.doi.org/10.1016/j.retram.2021.103312 |
| work_keys_str_mv | AT bouayadabdellatif hlaandpf4antibodyproductionafteradenoviralvectorsarscov2vaccination |